Oncotelic Therapeutics Secures $157K Convertible Note with Highly Dilutive Terms

summarizeSummary

Oncotelic Therapeutics obtained a $157,000 convertible note with an original issue discount, high interest, and dilutive conversion terms, reflecting the company's urgent need for capital amidst a 'going concern' warning.

check_boxKey Events · Financing and Capital Events · OTLC

• Secured Convertible Note

  On June 23, 2026, the company entered into a Securities Purchase Agreement for a convertible promissory note with a gross principal of $178,410, providing $157,000.80 in cash after a 12% original issue discount.

• Dilutive Conversion Terms

  The note carries a 12% annual interest rate and is convertible into common stock at a fixed price of $0.06 or 85% of the lowest traded price, whichever is lower, leading to potential significant dilution.

• Commitment Shares Issued

  Pacific Pier Capital II, LP received 500,000 shares of common stock as commitment shares.

• Aggressive Default Provisions

  The note includes events of default such as failure to maintain a $10 million market capitalization or uplist to NASDAQ within six months, triggering a 150% repayment penalty on the outstanding principal and interest.

auto_awesomeAnalysis · OTLC · Life Sciences

Oncotelic Therapeutics, which recently reported a 'going concern' warning, has secured a small convertible promissory note for $157,000.80. The financing comes with an original issue discount, a high interest rate, and a conversion price that floats at 85% of the lowest traded price, indicating significant dilution for existing shareholders. The note also includes aggressive default clauses, such as a 150% repayment penalty and requirements to maintain a minimum market capitalization and uplist to NASDAQ, highlighting the company's precarious financial position and the high cost of capital.